Description
Bremelanotide (research designation PT-141) is a synthetic cyclic heptapeptide derived through structural modification of the endogenous neuropeptide alpha-melanocyte-stimulating hormone (α-MSH) [1]. The compound belongs to the melanocortin receptor agonist class and retains the core pharmacophoric sequence found in native melanocortins while exhibiting enhanced metabolic stability relative to its linear precursors [6]. Its cyclic architecture is a defining structural feature that has made it a frequently selected tool compound for probing melanocortin receptor biology in preclinical model systems.
Bremelanotide demonstrates binding activity at multiple melanocortin receptor subtypes, with particularly notable affinity for MC4R, a receptor subtype whose central expression has drawn considerable attention from researchers investigating neuroendocrine signaling pathways [1]. The broader melanocortin system, which encompasses MC1R through MC5R, is implicated in a range of physiological processes including energy homeostasis, immune modulation, and behavioral responses, making melanocortin-targeting peptides valuable instruments across several research disciplines [2].
Within the laboratory setting, bremelanotide serves as an investigative probe for studies centered on melanocortin pathway mapping, central nervous system signaling, and the receptor-level mechanisms underlying neuroendocrine regulation. Researchers have employed it alongside complementary melanocortin ligands to delineate the distinct contributions of individual receptor subtypes to observed biological phenomena [2]. Its well-characterized receptor binding profile provides a defined pharmacological baseline against which novel compounds and experimental manipulations can be benchmarked in controlled in vitro and preclinical study designs.
---
References
[1] Bremelanotide: First Approval. Drugs, 2019. https://pubmed.ncbi.nlm.nih.gov/31429064/
[2] Targeting the central melanocortin system for the treatment of metabolic disorders. Nature Reviews Endocrinology, 2023. https://pubmed.ncbi.nlm.nih.gov/37365323/
[6] Bremelanotide. Wikipedia. https://en.wikipedia.org/wiki/Bremelanotide
